
Video: Manisha Bahl, MD, Discusses the Recent ACP Guidance on Breast Cancer Screening
In a recent interview with Diagnostic Imaging, Manisha Bahl, MD, MPH, SBI, offers pertinent insights on the controversial breast cancer screening guidance recently issued by the American College of Physicians (ACP).
Commenting on the recently published breast cancer screening guidance from the American College of Physicians (ACP), Manisha Bahl, MD, MPH, FSBI, said biennial mammography exams in contrast to annual mammography may significantly compromise early detection.
“The concern with biennial screening is that cancers can develop and grow in the interval between exams. Annual screening offers more frequent opportunities to detect cancer earlier before it becomes larger or metastasizes. In clinical practice, many women in their 40s benefit from annual screening, particularly because cancers in younger women can be more aggressive,” noted Dr. Bahl, an associate professor of radiology at Harvard Medical School and a breast radiologist affiliated with Massachusetts General Hospital.
In a recent interview with Diagnostic Imaging, Dr. Bahl emphasized the consensus of the American College of Radiology (ACR), Society of Breast Imaging (SBI), the American Society of Breast Surgeons and the National Comprehensive Cancer Network (NCCN) in starting breast cancer screening at the age of 40 for asymptomatic, average-risk women. In contrast, the ACP guidance suggests biennial mammography screening for women in their 40s after consultation with their doctor.
“Earlier and more regular screening increases the opportunity to detect cancers at a smaller size and earlier stage when treatment is less intensive and outcomes are better,” said Dr. Bahl.
While the ACP guidance suggests the possibility of discontinuing mammography screening in women 75 and older, Dr. Bahl emphasized that age should not be a limitation.
“Age alone should not determine whether screening stops. Many women in their 70s and beyond are healthy, active and have meaningful life expectancy. Breast cancer incidence remains relatively high in older women while false positive rates are generally lower than in younger women. The key issues are overall health status, functional status and patient preference,” maintained Dr. Bahl.
(Editor’s note: For related content, see “















